Skip To Main Content
Yingfeng Lin on Muck Rack

Yingfeng Lin

As seen in: MDPI, Canadian Journal of Cardiology, International Journal of Cardiology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Yingfeng

Contact Yingfeng, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Plants | Free Full-Text | Genome-Wide Identification and Characterization of the HAK Gene Family in Quinoa (Chenopodium quinoa Willd.) and Their Expression Profiles under Saline and Alkaline Conditions

|
By Yanqiong Chen, Yingfeng Lin, Shubiao Zhang, Zhongyuan Lin
| MDPI
This is an early access version, the complete PDF, HTML, and XML versions will be available soon.
Open in Who Shared Issue with article?

Clinical efficacy and safety outcomes of bempedoic acid for LDL-C lowering therapy in patients at high cardiovascular risk: a systematic review and meta-analysis

|
By Yingfeng Lin, Claudio Parco, Athanasios Karathanos, Torben Krieger
Yingfeng Lin1, Claudio Parco1, Athanasios Karathanos1, Torben Krieger1, Volker Schulze1, Nadja Chernyak2, Andrea Icks2, http://orcid.org/0000-0001-5834-2757Malte Kelm1,3, Maximilian Brockmeyer1, http://orcid.org/0000-0002-1734-6177Georg Wolff1 1Division of Cardiology, Pulmonology and Vascular Medicine, Department of Internal Medicine, Medical Faculty, Heinrich Heine University Düsseldorf, Düsseldorf, Germany 2Institute for Health Services Research and Health Economics, Centre for Health and...
Open in Who Shared Issue with article?

Routine Glycoprotein IIb/IIIa Inhibitor Therapy in ST-Segment Elevation Myocardial Infarction: A Meta-Analysis

|
By Yingfeng Lin, Lisa Dannenberg, Athanasios Karathanos, Claudio Parco
| Canadian Journal of Cardiology Verified
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Figure 1 All-cause mortality. Figure 1, legend: All-cause mortality outcome of routine GPI vs. control therapy in STEMI: A) All-cause mortality at a median of 30d; B) All-cause mortality at a median of 6 months. Individual and summary risk ratios with 95% confidence intervals; M-H=Mantel-Haenszel estimates with a fixed-effects model. Figure 2 Efficacy outcomes.
Open in Who Shared Issue with article?
See all 5 articles